GlassScriptPhysician profile
David Brooks Duff
NPI 1689055964
$1,281.04
in general payments reported to CMS, 2019-2025
10 companies · $270 in 2025
The $270 reported for 2025 was more than what 85% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2021: $189 · 2022: $115 · 2023: $79.99 · 2024: $335 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $604.38 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $269.72 | 2025 | |
| Edwards Lifesciences Corporation | $194.33 | 2024 | Hemosphere |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $186.73 | 2019-2021 | |
| Nevro Corp. | $146.55 | 2019 | |
| Genzyme Corporation | $124.99 | 2021 | |
| Incyte Corporation | $117.39 | 2022-2024 | Opzelura |
| Pfizer INC. | $112.65 | 2024 | |
| Sun Pharmaceutical Industries INC. | $79.99 | 2023 | |
| Merck Sharp & Dohme LLC | $25.47 | 2022 | |
| Ethicon INC. | $23.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Duff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.